PT3810283T - Formas sólidas do sal tartarato de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, processo para a sua preparação e métodos para a sua utilização no tratamento de cancros - Google Patents
Formas sólidas do sal tartarato de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, processo para a sua preparação e métodos para a sua utilização no tratamento de cancrosInfo
- Publication number
- PT3810283T PT3810283T PT197453350T PT19745335T PT3810283T PT 3810283 T PT3810283 T PT 3810283T PT 197453350 T PT197453350 T PT 197453350T PT 19745335 T PT19745335 T PT 19745335T PT 3810283 T PT3810283 T PT 3810283T
- Authority
- PT
- Portugal
- Prior art keywords
- phenyl
- difluoropropan
- fluoropropyl
- azetidin
- pyrido
- Prior art date
Links
- GQCXHIKRWBIQMD-AKJBCIBTSA-N 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol Chemical compound FC1=C(C(=CC(=C1)NC1CN(C1)CCCF)F)[C@H]1N([C@@H](CC2=C1NC1=CC=CC=C21)C)CC(CO)(F)F GQCXHIKRWBIQMD-AKJBCIBTSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- 125000004076 pyridyl group Chemical group 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862687930P | 2018-06-21 | 2018-06-21 | |
US201862719896P | 2018-08-20 | 2018-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3810283T true PT3810283T (pt) | 2023-08-18 |
Family
ID=67441580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT197453350T PT3810283T (pt) | 2018-06-21 | 2019-06-17 | Formas sólidas do sal tartarato de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, processo para a sua preparação e métodos para a sua utilização no tratamento de cancros |
Country Status (29)
Country | Link |
---|---|
US (2) | US10954234B2 (pt) |
EP (2) | EP3810283B1 (pt) |
JP (4) | JP6916969B1 (pt) |
KR (2) | KR20230117761A (pt) |
CN (2) | CN112437685A (pt) |
AU (3) | AU2019290545B2 (pt) |
BR (1) | BR112020024073A2 (pt) |
CA (1) | CA3098203A1 (pt) |
CL (1) | CL2020003022A1 (pt) |
CO (1) | CO2020014604A2 (pt) |
CR (2) | CR20230409A (pt) |
DK (1) | DK3810283T3 (pt) |
ES (1) | ES2951829T3 (pt) |
FI (1) | FI3810283T3 (pt) |
HR (1) | HRP20230859T1 (pt) |
HU (1) | HUE064542T2 (pt) |
IL (1) | IL278063A (pt) |
LT (1) | LT3810283T (pt) |
MX (3) | MX2020011531A (pt) |
PE (1) | PE20211207A1 (pt) |
PH (1) | PH12020500676A1 (pt) |
PL (1) | PL3810283T3 (pt) |
PT (1) | PT3810283T (pt) |
RS (1) | RS64429B1 (pt) |
SG (1) | SG11202012171SA (pt) |
SI (1) | SI3810283T1 (pt) |
TW (1) | TW202016098A (pt) |
UA (1) | UA128114C2 (pt) |
WO (1) | WO2019245974A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2951829T3 (es) | 2018-06-21 | 2023-10-25 | Hoffmann La Roche | Formas sólidas de la sal de tartrato de 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropil)acetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, proceso para su preparación y procedimientos de su uso en el tratamiento de cánceres |
EP4106760A4 (en) * | 2020-05-07 | 2024-03-27 | Recurium Ip Holdings Llc | COMBINATIONS |
US11918561B2 (en) | 2020-05-12 | 2024-03-05 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor |
US20230348459A1 (en) * | 2020-05-15 | 2023-11-02 | Simcere Pharmaceutical Co., Ltd. | Pyrrolidine compound and use thereof |
JP7419575B2 (ja) | 2020-06-28 | 2024-01-22 | メッドシャイン ディスカバリー インコーポレイテッド | 縮合環インダゾール系化合物 |
PE20230853A1 (es) | 2020-06-30 | 2023-05-29 | Genentech Inc | Procesos para elaborar compuestos serd triciclicos que tienen un resto sustituido de fenilo o piridinilo |
EP4267578A1 (en) | 2020-12-23 | 2023-11-01 | Recurium IP Holdings, LLC | Estrogen receptor modulators |
TW202237099A (zh) * | 2021-02-16 | 2022-10-01 | 美商建南德克公司 | 使用包含gdc-9545及帕他色替之組合療法治療乳癌 |
IL304911A (en) * | 2021-02-16 | 2023-10-01 | Genentech Inc | Breast cancer treatment using combination therapies including GDC-9545 and abemciclib or ribociclib |
CN117813288A (zh) | 2021-07-15 | 2024-04-02 | 西藏海思科制药有限公司 | 芳氨基衍生物***受体调节剂及其用途 |
CN114656444A (zh) * | 2022-03-04 | 2022-06-24 | 河北松辰医药科技有限公司 | 一种2,2-二氟-1,3-丙基磺酸内酯的合成方法 |
WO2023209062A1 (en) | 2022-04-28 | 2023-11-02 | F. Hoffmann-La Roche Ag | Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate |
CN115872996B (zh) * | 2023-02-21 | 2023-05-05 | 山东绿叶制药有限公司 | 一种***受体降解剂化合物及其制备方法和应用 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7414572L (pt) | 1973-12-06 | 1975-06-09 | Endo Lab | |
SE455604B (sv) | 1982-06-29 | 1988-07-25 | Stiftelsen Ind Organisk Elektr | Sett att framstella fenetylaminer medelst elektrokemisk reduktion |
DE3639329C1 (de) | 1986-11-18 | 1988-02-25 | Heesemann Karl Masch | Bandschleifmaschine |
US5206377A (en) | 1991-12-05 | 1993-04-27 | Whitby Research, Inc. | Compounds useful as antiproliferative agents |
EP0620222A3 (en) | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
RU14873U1 (ru) | 2000-06-26 | 2000-09-10 | Закрытое акционерное общество "Патентные услуги" | Комбинированная машина непрерывного литья заготовок |
ATE298570T1 (de) | 2000-12-08 | 2005-07-15 | Smithkline Beecham Corp | Antibakterielle verbindungen |
JP4220779B2 (ja) | 2001-02-12 | 2009-02-04 | リリー アイコス リミテッド ライアビリティ カンパニー | 化学化合物 |
US6951961B2 (en) | 2002-05-17 | 2005-10-04 | Marina Nikolaevna Protopopova | Methods of use and compositions for the diagnosis and treatment of infectious disease |
TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
WO2004089470A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | New amide derivatives and pharmaceutical use thereof |
WO2005034857A2 (en) | 2003-09-05 | 2005-04-21 | Sequella, Inc. | Methods and compositions comprising diamines as new anti-tubercular therapeutics |
RU2387652C2 (ru) | 2004-03-11 | 2010-04-27 | Актелион Фармасьютиклз Лтд | Производные тетрагидропиридоиндола |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
SG184755A1 (en) | 2004-03-15 | 2012-10-30 | Ptc Therapeutics Inc | Carboline derivatives useful in the inhibition of angiogenesis |
US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
EP1786425A1 (en) | 2004-08-02 | 2007-05-23 | SmithKline Beecham Corporation | Useful compounds for hpv infection |
WO2007002051A1 (en) | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
EP1968934A4 (en) | 2006-01-02 | 2014-02-26 | Hetero Drugs Ltd | METHOD FOR OBTAINING PURE OSELTAMIVIR |
AU2008239598A1 (en) | 2007-04-13 | 2008-10-23 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
MX2010011868A (es) | 2008-04-29 | 2010-11-26 | Novartis Ag | Derivados de espiro-indol para el tratamiento de enfermedades parasitarias. |
US9292307B2 (en) | 2008-07-30 | 2016-03-22 | Kyocera Corporation | User interface generation apparatus |
WO2010015815A2 (en) | 2008-08-05 | 2010-02-11 | Summit Corporation Plc | Compounds for the treatment of flaviviral infections |
EP2323652A2 (en) | 2008-08-06 | 2011-05-25 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
WO2010029313A1 (en) | 2008-09-11 | 2010-03-18 | Summit Corporation Plc. | Antiinfective compounds |
WO2010049678A2 (en) | 2008-10-31 | 2010-05-06 | Summit Corporation Plc | Treatment of energy utilization diseases |
WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
US20120046242A1 (en) | 2008-12-24 | 2012-02-23 | Massachusetts Institute Of Technology | Molecular activators of the wnt/beta-catenin pathway |
DE102009006545B4 (de) | 2009-01-29 | 2017-08-17 | Epcos Ag | Überspannungsableiter und Anordnung von mehreren Überspannungsableitern zu einem Array |
WO2010107485A1 (en) | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | E3 ligase inhibitors |
AU2010232642A1 (en) | 2009-03-31 | 2011-10-20 | Arqule, Inc. | Substituted indolo-piperidine compounds |
WO2010138685A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
US20120157401A1 (en) | 2009-05-27 | 2012-06-21 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
MX2020005345A (es) | 2009-05-27 | 2022-07-18 | Ptc Therapeutics Inc | Un método para inhibir o reducir una infección viral por coronavirus. |
WO2010138652A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating kaposi sarcoma |
US20120157402A1 (en) | 2009-05-27 | 2012-06-21 | Liangxian Cao | Methods for treating brain tumors |
WO2010138706A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating breast cancer |
WO2011150162A1 (en) | 2010-05-27 | 2011-12-01 | Ptc Therapeutics, Inc. | Methods for treating viral conditions |
HUE033581T2 (hu) | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
CA2819299A1 (en) | 2010-12-24 | 2012-06-28 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
CA2857057A1 (en) | 2011-12-14 | 2013-06-20 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
CN104508126B (zh) | 2012-03-23 | 2017-06-30 | 科德克希思公司 | 用于合成色胺和色胺类似物的衍生物的生物催化剂和方法 |
WO2013139987A1 (en) | 2012-03-23 | 2013-09-26 | Novartis Ag | Chemical process for preparing spiroindolones and intermediates thereof |
EP2682119A1 (en) | 2012-07-03 | 2014-01-08 | Université Libre de Bruxelles | Aromatic N-heterocycle derivatives for use as medicine |
EP2738173A1 (en) | 2012-11-28 | 2014-06-04 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Heterocyclic compounds as inhibitors of the sodium iodide symporter |
US9643982B2 (en) | 2013-05-17 | 2017-05-09 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
SI3004090T1 (en) | 2013-05-28 | 2018-01-31 | Astrazeneca Ab | Chemical compounds |
CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
SG11201509508YA (en) | 2013-06-19 | 2015-12-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulator and uses thereof |
WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
EP3062791B1 (en) | 2013-10-28 | 2020-01-08 | Drexel University | Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder |
MX2016007282A (es) | 2013-12-06 | 2016-09-07 | Hoffmann La Roche | Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico. |
RU2016137150A (ru) | 2014-03-13 | 2018-04-18 | Ф. Хоффманн-Ля Рош Аг | Способы и композиции для модулирования мутантов эстрогеновых рецепторов |
MA39741A (fr) | 2014-03-13 | 2017-01-18 | Hoffmann La Roche | Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes |
KR102505901B1 (ko) | 2014-06-27 | 2023-03-08 | 노그라 파마 리미티드 | 아릴 수용체 조정제, 및 그의 제조 및 사용 방법 |
CN107406424B (zh) | 2014-12-18 | 2020-08-25 | 豪夫迈·罗氏有限公司 | ***受体调节剂及其用途 |
JP2017538727A (ja) | 2014-12-18 | 2017-12-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 癌の治療に有用な2,3−ジフェニルクロメンの誘導体 |
EA032311B1 (ru) * | 2014-12-18 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение |
JP6776348B2 (ja) | 2015-10-01 | 2020-10-28 | オレマ ファーマシューティカルズ インク. | テトラヒドロ−1H−ピリド[3,4−b]インドール抗エストロゲン薬物 |
EP3954372A1 (en) * | 2016-02-01 | 2022-02-16 | Takeda Pharmaceutical Company Limited | Cocrystal |
WO2017136688A1 (en) | 2016-02-05 | 2017-08-10 | Inventisbio Inc. | Selective estrogen receptor degraders and uses thereof |
EP3472159A1 (en) * | 2016-06-16 | 2019-04-24 | F. Hoffmann-La Roche AG | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
JP7018026B2 (ja) * | 2016-06-16 | 2022-02-09 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | ヘテロアリールエストロゲン受容体モジュレーター及びその使用 |
ES2951829T3 (es) | 2018-06-21 | 2023-10-25 | Hoffmann La Roche | Formas sólidas de la sal de tartrato de 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropil)acetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, proceso para su preparación y procedimientos de su uso en el tratamiento de cánceres |
-
2019
- 2019-06-17 ES ES19745335T patent/ES2951829T3/es active Active
- 2019-06-17 DK DK19745335.0T patent/DK3810283T3/da active
- 2019-06-17 CN CN201980041221.4A patent/CN112437685A/zh active Pending
- 2019-06-17 MX MX2020011531A patent/MX2020011531A/es unknown
- 2019-06-17 RS RS20230634A patent/RS64429B1/sr unknown
- 2019-06-17 SG SG11202012171SA patent/SG11202012171SA/en unknown
- 2019-06-17 CN CN202410165649.2A patent/CN117946107A/zh active Pending
- 2019-06-17 CA CA3098203A patent/CA3098203A1/en active Pending
- 2019-06-17 LT LTEPPCT/US2019/037492T patent/LT3810283T/lt unknown
- 2019-06-17 HR HRP20230859TT patent/HRP20230859T1/hr unknown
- 2019-06-17 PL PL19745335.0T patent/PL3810283T3/pl unknown
- 2019-06-17 HU HUE19745335A patent/HUE064542T2/hu unknown
- 2019-06-17 PT PT197453350T patent/PT3810283T/pt unknown
- 2019-06-17 KR KR1020237026161A patent/KR20230117761A/ko active IP Right Grant
- 2019-06-17 KR KR1020217001924A patent/KR102564647B1/ko active IP Right Grant
- 2019-06-17 WO PCT/US2019/037492 patent/WO2019245974A1/en active Application Filing
- 2019-06-17 CR CR20230409A patent/CR20230409A/es unknown
- 2019-06-17 BR BR112020024073-7A patent/BR112020024073A2/pt unknown
- 2019-06-17 UA UAA202100182A patent/UA128114C2/uk unknown
- 2019-06-17 JP JP2020570698A patent/JP6916969B1/ja active Active
- 2019-06-17 FI FIEP19745335.0T patent/FI3810283T3/fi active
- 2019-06-17 SI SI201930592T patent/SI3810283T1/sl unknown
- 2019-06-17 CR CR20200621A patent/CR20200621A/es unknown
- 2019-06-17 EP EP19745335.0A patent/EP3810283B1/en active Active
- 2019-06-17 PE PE2020001888A patent/PE20211207A1/es unknown
- 2019-06-17 US US16/443,515 patent/US10954234B2/en active Active
- 2019-06-17 TW TW108120952A patent/TW202016098A/zh unknown
- 2019-06-17 AU AU2019290545A patent/AU2019290545B2/en active Active
- 2019-06-17 EP EP23178559.3A patent/EP4295845A3/en active Pending
-
2020
- 2020-10-15 IL IL278063A patent/IL278063A/en unknown
- 2020-10-29 MX MX2023006785A patent/MX2023006785A/es unknown
- 2020-10-29 MX MX2022016065A patent/MX2022016065A/es unknown
- 2020-11-20 CL CL2020003022A patent/CL2020003022A1/es unknown
- 2020-11-25 CO CONC2020/0014604A patent/CO2020014604A2/es unknown
- 2020-12-03 US US17/110,607 patent/US11780834B2/en active Active
- 2020-12-17 PH PH12020500676A patent/PH12020500676A1/en unknown
-
2021
- 2021-07-16 JP JP2021117633A patent/JP2021191750A/ja active Pending
- 2021-07-16 JP JP2021117638A patent/JP2021191751A/ja active Pending
-
2022
- 2022-05-03 AU AU2022202967A patent/AU2022202967B2/en active Active
-
2023
- 2023-09-13 AU AU2023229513A patent/AU2023229513A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002374A patent/JP2024054111A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL278063A (en) | Solid forms of 3-((R3,R1)-1-(6,2-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-9,4 3,1-tetrahydro-H2-pyrido[4,3-B]indol-2-yl]2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds containing a substituted phenyl or pyridinyl residue, including methods for using them | |
HRP20211261T8 (hr) | [1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indola | |
ZA200806066B (en) | Process for the preparation of 6,6-dimethyl-3-azabicyclo[3.1.0]-hexane compounds and enantiomeric salts thereof | |
SG11202005641XA (en) | Enantiomeric separation of racemic nicotine by addition of an o,o'-disubstituted tartaric acid enantiomer | |
ZA200702097B (en) | Process for the preparation of enantiomers of amidoacetonitrile compounds from their racemates | |
WO2009145590A3 (en) | Phenyl piperazine compounds, pharmaceutical composition comprising the same, and use thereof | |
EP2242364A4 (en) | PREPARATION AND SANANTIOMERIC SEPARATION OF NONANE OF 7- (3-PYRIDINYL) -1,7-DIAZASPIROÝ4.4 AND NEW FORMS OF SALT OF RACEMATE AND ENANTIOMERS | |
IL281025A (en) | Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-inol)-pyrrolidine-2-YL]imidazo[1,5-A]-pyrazine-1-YL}N- (pyridine-2-YL)-benzamide | |
HUE051212T2 (hu) | Kondenzált fenilgyûrût tartalmazó C-glükozid származék vagy annak gyógyászatilag elfogadható sója, eljárás annak elõállítására és azt tartalmazó gyógyászati kompozíció | |
AR114974A1 (es) | Procesos para preparar compuestos tricíclicos fusionados que comprenden un resto piridinilo o fenilo sustituido, incluidos métodos para su uso | |
LT3655395T (lt) | N-((1r,2s,sr)-5-(tret-butilamino)-2-((s)-3-(7-tret-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oksopirolidin-1-il)cikloheksil)acetamido gamybos būdas | |
AU2003222435A8 (en) | Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile | |
PL3643704T3 (pl) | Nowe produkty pośrednie do wytwarzania chlorowodorku remifentanilu | |
WO2007056403A3 (en) | Asymmetric hydrogenation of acyl enamides | |
PT3601298T (pt) | Processo para preparar compostos quirais de 2,3-dihidrotiazolo[ 3,2-a]pirimidina-4-ium | |
SI3164385T1 (sl) | Nova polimorfna oblika N-(2-(6-fluoro-LH-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoksi) benzilamin hidroklorida za zdravljenje Alzheimerjeve bolezni | |
WO2012095871A3 (en) | Polymorphism in 5-amino- 1 -(2,6-dichloro-4- trifluoromethylphenyl)-3-cyano-4-trifluoro methyl sulfinyl pyrazole | |
TH91931A (th) | การใช้แบบใหม่ของเอสซิแทลอแพรม |